ImmunityBio, Inc. (XETR:26CA) Financings

ImmunityBio, Inc.

Financings

RaiseDate
Registered direct offering of common stock and warrants
Announced: about US$80M · Piper Sandler & Co.
Dealers: Piper Sandler & Co. (lead)
Use of proceeds: Further working capital and support for ongoing business operations
Jul 25, 2025
Registered direct offering of common stock and warrants
Announced: about US$75M · warrants for the purchase of additional shares of common stock; if fully exercised,…
Buyers: single institutional investor
Use of proceeds: Working capital and ongoing business operations
Apr 8, 2025
Public offering of common stock
Update: about US$100M · US$3 a share · Jefferies +4
Dealers: Jefferies (co-lead), Piper Sandler (co-lead), BTIG (co-lead), H.C. Wainwright & Co. (co-lead), D. Boral Capital
Use of proceeds: Commercialization of ANKTIVA for bladder cancer, trials in BCG-naive NMIBC and NSCLC, R&D, working capital and general corporate purposes
Dec 11, 2024

Read by 6ix AI from the company's releases